myelofibrosis
Haematology · 2013–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fedratinib Treatment of intermediate-2 and high-risk myelofibrosis (primary, post-polycythaemia vera, or post-essential thrombocythaemia) who have had prior ruxolitinib… | May 2025 | Not recommended | 8 individuals Leukaemia Foundation · Alliance Australia · MPN Alliance |
| fedratinib Treatment of patients with intermediate-2/high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia… | Nov 2025 | Recommended with restriction | 1 individuals Alliance Australia · Rare Cancers Australia · MPN Alliance Australia |
| momelotinib Intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in patients with… | Nov 2024 | Recommended with restriction | 16 individuals |
| ruxolitinib First-line or second-line management of myelofibrosis (primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia… | Jul 2016 | Recommended | none received |
| ruxolitinib First-line or second-line management of myelofibrosis in patients with intermediate-2 or high-risk disease, or intermediate-1 risk with severe symptoms… | Mar 2015 | Recommended with restriction | none received |
| ruxolitinib Second-line management of myelofibrosis in patients with intermediate-2 or high-risk disease (IPSS) who are resistant, refractory, intolerant, or not a… | Jul 2014 | Recommended with restriction | 2 individuals |
| ruxolitinib Treatment of disease-related symptoms in patients with intermediate or high-risk primary (idiopathic) myelofibrosis, post-polycythemia vera myelofibrosis or… | Jul 2013 | Not recommended | unclear |
Who spoke
Alliance Australia · Leukaemia Foundation · MPN Alliance · Rare Cancers Australia · MPN Alliance Australia
What the PBS pays
$116M in government benefit over 2024–25, across 25,422 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ruxolitinib | $113.4M |
| momelotinib | $3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 3 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| fedratinibFedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | recommended restricted | 2024-11 |
| momelotinibMomelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | recommended restricted | 2024-03 |
| ruxolitinibRuxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | recommended restricted | 2016-03 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.